Status:
TERMINATED
Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)
Lead Sponsor:
Pfizer
Conditions:
Aspergillosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will test the effectiveness and the safety of giving two antifungal agents (voriconazole and anidulafungin) together to treat invasive aspergillosis in patients who are unable to tolerate p...
Detailed Description
The study was terminated on January 12, 2009 due to the overall low rate of enrollment. The decision to terminate the trial was not based on any safety concerns. Patients who were enrolled in the stud...
Eligibility Criteria
Inclusion
- Proven or probable invasive aspergillosis. Patient is intolerant to polyene therapy.
Exclusion
- Patients with invasive aspergillosis for more than 30 days at the time of study entry. Patients with uncontrolled bacterial or viral infection at the time of study entry. Patients with significant liver dysfunction or who are taking certain medications which interact with voriconazole.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00620074
Start Date
August 1 2008
End Date
February 1 2009
Last Update
February 15 2010
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Atlanta, Georgia, United States, 30322
2
Pfizer Investigational Site
Detroit, Michigan, United States, 48202
3
Pfizer Investigational Site
Fort Worth, Texas, United States, 76104
4
Pfizer Investigational Site
Fort Worth, Texas, United States, 76107